The Kaiser Family Foundation (KFF) recently released a study that showed that 42% of Americans are unaware that Obamacare (the Affordable Care Act) remains the “law of the land.” News like this seems to us, to act as a Rorschach test on how observers feel about the law. Considering 50% of Americans can’t identify New York on a map we tend not to read too much into these polls. However, according to the logic of extrapolation, since we know that the ACA remains law, we are in the elite 58% (it’s about time we made it into the elite of something).

In almost parallel to the KFF news, the New England Journal of Medicine published a follow-up study of the “Oregon experiment.” For those who haven’t been following closely, the study found that previously uninsured people who were enrolled in Medicaid did not see an improvement in clinical measures when compared to those who remained uninsured. The study did seem to show a reduction in the amount of financial distress for the insured however.

Another contentious study, another Rorschach test (example, example). The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof. In light of the fact that for most practical matters ACA doesn’t really get going until 2014, use of the extrapolation noise generator approach smacks of a lack of analytical rigor in our view. We will know soon enough how the program is doing… exchanges start enrolling on 10/1.

As investors, we should state upfront that we tend to give more weight to financial returns than what the philosopher-kings might call the political context. So what caught our eye in the Oregon study was that Medicaid recipients had higher healthcare utilization rates (and associated costs) than the uninsured. The connection between gaining insured status and healthcare utilization should not come as a surprise since there is a very extensive literature elucidating this connection.

We have noticed that many in the political community, especially where it pertains to entitlements, have taken an absolutist utilization=bad view of the world. At Poliwogg we take a more nuanced approach. We view healthcare expenditures not as a cost but as the creation of an asset. In our framework, utilization can be categorized as generating either a positive return or a negative return depending on the outcome. If the expenditure creates additional value it is good, if it does not than it is bad. We would take a good pharmaceutical over a bad diagnostic test any day despite the former often being more expensive upfront.

To be fair, it is not always easy to determine a priori whether utilization will have a positive or negative consequence longer-term. And it should be noted that the system does have significant inertia hard-wired into it (prior mis-allocation of resources, a mal-incentive based reimbursement structure and asymmetry of information, among other things) which needs to be overcome. Nevertheless, there are signs that some things have changed recently to offer some glimmers of hope of a possibility of value creation and system enhancement. Like it or not, ACA is a change-agent and it will alter the status quo. The impact of improvement in technology and telecommunication, which allows for more real-time observation of events and predictive analytics, is first being felt. And, given the downward trajectory of utilization connected to the recent economic downturn it’s a pretty good supposition that healthcare costs (after many decades of rising) are finally starting to alter behavior on the part of patients and providers.

With respect to investing, uncertainly caused by media/pundit noise often depresses valuations in the short run. We suggest investors avoid the extrapolation machine and stick to observing fundamentals and fact. In the context of healthcare, as we see it, this means focusing on a double bottom line: companies with financial return potential (at the appropriate risk level) and companies who create value through innovation either by improving quality or meeting a need (especially true in the case of therapeutics for many currently poorly-treated diseases). If investors do this they can let the extrapolation machine work for them rather than exacerbate the problem.

Les Funtleyder is the managing director of Poliwogg, where this post originally appeared.

Share on Twitter

3 Responses for “Into the Extrapolation Machine”

  1. Dr. Z says:

    Better title for this post would have been “The Wild Extrapolation Machine.”

    This is perhaps the single best one line description of ACA I’ve come across.

    “The problem we see with the polarity of views is that both sides seem to be cranking up the extrapolation machine and use single studies/data points to draw broad conclusions to gin up opinions about ACA’s success or lack thereof”

  2. Bobby Gladd says:

    I posted this on my REC blog in response to the Oregon “findings” -
    __

    “I’m now a Medicare bene. 67 years old, with the usual litany of manageable (and managed) afflictions that come mostly with having lived this long. I’m a 99214, a “moderately complex established patient.”

    I see my doc twice a year. Lab pulls annually (blood and urine, the usual broad panels).

    On a couple of generic maintenance meds. You can likely guess what they are.

    I’m an uncontrolled, marginally “comparative effects research” experiment. Statistically df=3 at n-1 (4 visits in 2 years). Were I seeing my doc four times a year, n-1 df=15. For those few who took anything away from undergrad stats courses, this is “Inadequate Sample Size 101.” (See “Standard Error of the Mean,” “Power Analysis.”)

    Medicaid hating “conservatives” are all over this NEJM article. It proves that Medicaid is “ineffective.”

    What crap. The Instant Gratification Culture, Policy Wonk Division, Run Amuck.”
    __

    Aggregating a bunch of patients to pump up the “n” is meaningless given the short time frame here.

  3. Better subject just for this post would’ve already been The Outrageous Extrapolation Machine.Nice post!!!!!!!

Leave a Reply

FROM THE VAULT

The Power of Small Why Doctors Shouldn't Be Healers Big Data in Healthcare. Good or Evil? Depends on the Dollars. California's Proposition 46 Narrow Networking
MASTHEAD STUFF

MATTHEW HOLT
Founder & Publisher

JOHN IRVINE
Executive Editor

JONATHAN HALVORSON
Editor

JOE FLOWER
Contributing Editor

MICHAEL MILLENSON
Contributing Editor

ALEX EPSTEIN
Director of Digital Media

MICHELLE NOTEBOOM Business Development

MUNIA MITRA, MD
Clinical Medicine

Vikram Khanna
Editor-At-Large, Wellness

THCB FROM A-Z

FOLLOW US ON TWITTER
@THCBStaff

WHERE IN THE WORLD WE ARE

The Health Care Blog (THCB) is based in San Francisco. We were founded in 2004 by Matthew Holt and John Irvine.

MEDIA REQUESTS

Interview Requests + Bookings. We like to talk. E-mail us.

BLOGGING
Yes. We're looking for bloggers. Send us your posts.

STORY TIPS
Breaking health care story? Drop us an e-mail.

CROSSPOSTS

We frequently accept crossposts from smaller blogs and major U.S. and International publications. You'll need syndication rights. Email a link to your submission.

WHAT WE'RE LOOKING FOR

Op-eds. Crossposts. Columns. Great ideas for improving the health care system. Pitches for healthcare-focused startups and business.Write ups of original research. Reviews of new healthcare products and startups. Data-driven analysis of health care trends. Policy proposals. E-mail us a copy of your piece in the body of your email or as a Google Doc. No phone calls please!

THCB PRESS

Healthcare focused e-books and videos for distribution via THCB and other channels like Amazon and Smashwords. Want to get involved? Send us a note telling us what you have in mind. Proposals should be no more than one page in length.

HEALTH SYSTEM $#@!!!
If you've healthcare professional or consumer and have had a recent experience with the U.S. health care system, either for good or bad, that you want the world to know about, tell us about it. Have a good health care story you think we should know about? Send story ideas and tips to editor@thehealthcareblog.com.

REPRINTS Questions on reprints, permissions and syndication to ad_sales@thehealthcareblog.com.

WHAT WE COVER

HEALTHCARE, GENERAL

Affordable Care Act
Business of Health Care
National health policy
Life on the front lines
Practice management
Hospital managment
Health plans
Prevention
Specialty practice
Oncology
Cardiology
Geriatrics
ENT
Emergency Medicine
Radiology
Nursing
Quality, Costs
Residency
Research
Medical education
Med School
CMS
CDC
HHS
FDA
Public Health
Wellness

HIT TOPICS
Apple
Analytics
athenahealth
Electronic medical records
EPIC
Design
Accountable care organizations
Meaningful use
Interoperability
Online Communities
Open Source
Privacy
Usability
Samsung
Social media
Tips and Tricks
Wearables
Workflow
Exchanges

EVENTS

TedMed
HIMSS South x South West
Health 2.0
WHCC
AHIP
AHIMA
Log in - Powered by WordPress.